FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).
What happened
FDA inspected the facility from March 30 to April 3, 2026 and reviewed complaint records. It found a filling technician reported passing tests for Oxygen, USP batches without performing them, and a hospital complaint led to third-party testing showing (b)(4) as high as 99% in containers labeled medical oxygen. FDA also cited missing identity testing for incoming medical gas and deficient investigations, including one into water in high-pressure oxygen.
What FDA found
The firm released Oxygen, USP batches without the required laboratory determination of identity and strength, and a technician reported passing results without performing the tests.
21 CFR 213.165(a)The firm did not test each incoming medical gas lot for identity and did not validate the reliability of supplier certificates of analysis.
21 CFR 213.82(a) and 213.82(b)The firm did not establish and follow adequate complaint procedures, including quality unit review and timely investigation of hospital complaints about (b)(4) and water in Oxygen, USP.
21 CFR 213.198(a)The quality unit lacked adequate authority and procedures to oversee medical gas manufacturing and current good manufacturing practice (CGMP) training.
21 CFR 213.22(a), 213.22(c), 213.25(a)
What FDA wants
FDA tells the company to promptly address the violations without delay and to provide detailed remediation plans and independent assessments covering laboratory testing, incoming medical gases, complaints and corrective and preventive action (CAPA), the quality unit, and data integrity.
Who should pay attention
- hospitals and clinics that buy or use medical oxygen
- medical gas distributors and fillers
- companies relying on supplier certificates of analysis for incoming gases
This is a summary. Read the original letter on fda.gov.